Sobi Advances Gamifant After Positive Phase 2a Data in Interferon-Gamma–Driven Sepsis

Swedish Orphan Biovitrum AB ( (SE:SOBI) ) just unveiled an announcement.

Sobi announced that topline phase 2a data from the EMBRACE trial of Gamifant (emapalumab) in patients with interferon-gamma–driven sepsis (IDS) in Greece support proof of concept, showing improvements in organ dysfunction and survival when added to standard care. On the back of these results, Sobi and its collaborator, the Hellenic Institute for the Study of Sepsis, plan to advance development of emapalumab for this newly defined sepsis endotype—associated with very high mortality—and will discuss next clinical and regulatory steps with authorities, potentially expanding Gamifant’s use beyond its current approvals in hemophagocytic lymphohistiocytosis and strengthening Sobi’s position in precision immunotherapy for severe inflammatory conditions.

The most recent analyst rating on (SE:SOBI) stock is a Hold with a SEK374.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

More about Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company focused on treatments for rare diseases, with a portfolio that includes immunology and hematology therapies such as Gamifant (emapalumab). Headquartered in Stockholm and listed on Nasdaq Stockholm, Sobi employs around 1,900 people across Europe, North America, the Middle East, Asia and Australia, and generated revenues of SEK 26 billion in 2024.

Average Trading Volume: 377,073

Technical Sentiment Signal: Buy

Current Market Cap: SEK115.1B

Find detailed analytics on SOBI stock on TipRanks’ Stock Analysis page.